Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (48)

2023

  1. Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes

    Diabetes Therapy, Vol. 14, Núm. 11, pp. 1771-1784

2022

  1. IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET)

    Trials, Vol. 23, Núm. 1

  2. IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity

    Trials, Vol. 23, Núm. 1

  3. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study

    Journal of Headache and Pain, Vol. 23, Núm. 1

  4. Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development

    International Journal of Molecular Sciences, Vol. 23, Núm. 15

2021

  1. Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

    Advances in Therapy, Vol. 38, Núm. 8, pp. 4442-4460

  2. IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG)

    Trials, Vol. 22, Núm. 1

  3. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 20-30

2020

  1. What is an efficient health intervention in Spain in 2020?

    Gaceta Sanitaria, Vol. 34, Núm. 2, pp. 189-193

2019

  1. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 12, pp. 1655-1669

  2. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

    European Journal of Cancer, Vol. 107, pp. 186-195

  3. Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients

    Breast

  4. Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies

    AAPS Journal, Vol. 21, Núm. 2

2018

  1. Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer

    European Journal of Pharmaceutical Sciences, Vol. 115, pp. 296-303

  2. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

2017

  1. Characterizing gemcitabine effects administered as single agent or combined with carboplatin in mice pancreatic and ovarian cancer xenografts: A semimechanistic pharmacokinetic/pharmacodynamics tumor growth-response model

    Journal of Pharmacology and Experimental Therapeutics, Vol. 360, Núm. 3, pp. 445-456

2016

  1. Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

    Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1

2015

  1. Can pentylenetetrazole and maximal electroshock rodent seizure models quantitatively predict antiepileptic efficacy in Humans?

    Seizure, Vol. 24, Núm. C, pp. 21-27

  2. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder

    European Neuropsychopharmacology, Vol. 25, Núm. 10, pp. 1611-1621

2014

  1. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 3, Núm. 5